[go: up one dir, main page]

FR2870539A1 - Nouvelles methodes et medicaments - Google Patents

Nouvelles methodes et medicaments

Info

Publication number
FR2870539A1
FR2870539A1 FR0405510A FR0405510A FR2870539A1 FR 2870539 A1 FR2870539 A1 FR 2870539A1 FR 0405510 A FR0405510 A FR 0405510A FR 0405510 A FR0405510 A FR 0405510A FR 2870539 A1 FR2870539 A1 FR 2870539A1
Authority
FR
France
Prior art keywords
medicines
new methods
prevention
derivatives
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0405510A
Other languages
English (en)
Other versions
FR2870539B1 (fr
Inventor
Philippe Pierre Bernard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Greenpharma SAS
Original Assignee
Greenpharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenpharma SAS filed Critical Greenpharma SAS
Priority to FR0405510A priority Critical patent/FR2870539B1/fr
Priority to PCT/FR2005/001260 priority patent/WO2005113517A1/fr
Priority to EP05773249A priority patent/EP1761507A1/fr
Publication of FR2870539A1 publication Critical patent/FR2870539A1/fr
Application granted granted Critical
Publication of FR2870539B1 publication Critical patent/FR2870539B1/fr
Priority to US11/601,778 priority patent/US20070161628A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/02—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne notamment de nouveaux dérivés stéréospécifiques de type 2,3-benzodiazépines comme inhibiteurs de phosphodiestérases, notamment 2 et 4 et leurs applications dans le domaine thérapeutique tout particulièrement pour la prévention et le traitement de pathologies impliquant un désordre central et/ou périphérique. Les composés de l'invention répondent plus particulièrement aux formules générales (I)et (II):
FR0405510A 2004-05-19 2004-05-19 Nouvelles methodes et medicaments Expired - Fee Related FR2870539B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR0405510A FR2870539B1 (fr) 2004-05-19 2004-05-19 Nouvelles methodes et medicaments
PCT/FR2005/001260 WO2005113517A1 (fr) 2004-05-19 2005-05-19 Composes inhibiteurs de phosphodiesterases
EP05773249A EP1761507A1 (fr) 2004-05-19 2005-05-19 Composes de type 2,3-benzodiazepines inhibiteurs de phosphodiesterases
US11/601,778 US20070161628A1 (en) 2004-05-19 2006-11-20 Phosphodiesterase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0405510A FR2870539B1 (fr) 2004-05-19 2004-05-19 Nouvelles methodes et medicaments

Publications (2)

Publication Number Publication Date
FR2870539A1 true FR2870539A1 (fr) 2005-11-25
FR2870539B1 FR2870539B1 (fr) 2006-08-04

Family

ID=34946844

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0405510A Expired - Fee Related FR2870539B1 (fr) 2004-05-19 2004-05-19 Nouvelles methodes et medicaments

Country Status (4)

Country Link
US (1) US20070161628A1 (fr)
EP (1) EP1761507A1 (fr)
FR (1) FR2870539B1 (fr)
WO (1) WO2005113517A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858620B2 (en) 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
UA102693C2 (ru) 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
CN103497098A (zh) * 2013-10-18 2014-01-08 南京华威医药科技开发有限公司 一种托非索泮中间体的制备方法
US20160206674A1 (en) 2013-12-24 2016-07-21 Biotropics Malaysia Bhd Fruit extracts and extract formulations of canarium odontophyllum as actives and related invention embodiments
EP3156405A1 (fr) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024400A1 (fr) * 1998-10-27 2000-05-04 Vela Pharmaceuticals Inc. Utilisation du tofisopam (r) optiquement pur pour traiter et prevenir les troubles de l'anxiete et sa composition
WO2002088096A1 (fr) * 2001-04-26 2002-11-07 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
WO2002098865A2 (fr) * 2001-06-07 2002-12-12 Neuro3D Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs
WO2004050080A1 (fr) * 2002-12-03 2004-06-17 Vela Pharmaceuticals, Inc. Traitement de troubles inflammatoires par des 2,3-benzodiazepines
WO2004073638A2 (fr) * 2003-02-19 2004-09-02 Vela Pharmaceuticals, Inc. Methode d'abaissement de la temperature du corps au moyen de (s)-2,3-benzodiazepines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK118660B (da) * 1966-12-09 1970-09-21 Egyt Gyogyszervegyeszeti Gyar Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid.
US6638928B1 (en) * 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024400A1 (fr) * 1998-10-27 2000-05-04 Vela Pharmaceuticals Inc. Utilisation du tofisopam (r) optiquement pur pour traiter et prevenir les troubles de l'anxiete et sa composition
WO2002088096A1 (fr) * 2001-04-26 2002-11-07 Neuro3D Composes inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations
WO2002098865A2 (fr) * 2001-06-07 2002-12-12 Neuro3D Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs
WO2004050080A1 (fr) * 2002-12-03 2004-06-17 Vela Pharmaceuticals, Inc. Traitement de troubles inflammatoires par des 2,3-benzodiazepines
WO2004073638A2 (fr) * 2003-02-19 2004-09-02 Vela Pharmaceuticals, Inc. Methode d'abaissement de la temperature du corps au moyen de (s)-2,3-benzodiazepines

Also Published As

Publication number Publication date
US20070161628A1 (en) 2007-07-12
WO2005113517A1 (fr) 2005-12-01
FR2870539B1 (fr) 2006-08-04
EP1761507A1 (fr) 2007-03-14

Similar Documents

Publication Publication Date Title
MA27668A1 (fr) 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
MA31183B1 (fr) Inhibiteurs de mek
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA28437B1 (fr) Composes et leurs procedes d'utilisation
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA24694A1 (fr) Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux, et compositions les contenant.
TN2009000471A1 (fr) Composes amino-heterocycliques
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
MA34559B1 (fr) Formulation pour le traitement du cancer
MA38099B1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA24729A1 (fr) Macrolides nouveaux.
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA30358B1 (fr) Quinazolines pour l'inhibition de pdk1
MA27556A1 (fr) Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
EP1819227A4 (fr) Formulation pharmaceutique de decitabine
MA28747B1 (fr) Dérivés de pyridine
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20120131